BMO Capital raised the firm’s price target on Disc Medicine to $70 from $50 and keeps an Outperform rating on the shares. The updates and management presentation at EHA give the firm “regained confidence” in Disc’s plan for bitopertin in erythropoietic protoporphyria, or EPP, says the analyst, who has increased the estimate of the odds of success for bitopertin in EPP/XLP to 70%. Additional updates from the hepcidin portfolio are “proving Disc is diversified beyond bitopertin,” added the analyst.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine Announces Underwritten Offering of Common Stock
- Disc Medicine Unveils Promising Clinical Trial Results at EHA Congress
- Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
- Disc Medicine to Participate in the Jefferies Global Healthcare Conference
- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
Questions or Comments about the article? Write to editor@tipranks.com